Unlike in breast or bladder cancer, the significant improvement in pathologic response in the PROTEUS trial did not translate to a similarly impressive benefit in metastasis-free survival. This disconnect suggests that eliminating tumor in the prostate specimen is not a reliable surrogate for long-term outcomes in this disease setting.

PROTEUS changed its primary endpoint mid-study to include PSMA PET-detected metastasis. While this led to a statistically positive result, it raises concerns that the benefit is merely earlier detection (lead-time bias) rather than a true improvement in curing micrometastatic disease and improving overall survival.

Patients in recent international adjuvant trials like MONARCH-E, NATALI, and LADERA have a significantly higher baseline risk of recurrence compared to those in US-centric studies like TaylorX. Three-year event rates are two to four times higher, which is critical context for applying these findings and assessing the cost-benefit of new, toxic therapies for average-risk patients.

An analysis of EMERALD and LEAP trial criteria against real-world HCC cases reveals that a majority of complex patients (e.g., multifocal, large tumors) who could most benefit from combination therapies were ineligible, cautioning clinicians against broad application of trial results.

The FRONT-MIND trial's positive result for Tafa-Len-R-CHOP must be contextualized. A key eligibility criterion was a diagnosis-to-treatment interval under 28 days. This selected for patients with rapidly progressing, aggressive disease, creating a higher-risk population than in other trials and likely explaining the R-CHOP arm's weaker performance.

When looking only at the original endpoint of metastasis-free survival by conventional imaging, the PROTEUS trial was not positive. This result is consistent with the negative ENZERAD trial, which tested a similar drug combination with radiation instead of surgery. This cross-trial consistency suggests adding an ARPI may not provide a substantial benefit in this setting.

An overall survival (OS) benefit in an adjuvant trial may not be meaningful for patients in systems (e.g., the U.S.) with guaranteed access to the same effective immunotherapy upon recurrence. The crucial, unanswered question is whether treating micrometastatic disease is inherently superior to treating macroscopic disease later, a distinction current trial data doesn't clarify.

Despite meeting its primary endpoint, the PROTEUS trial provides no validated biomarkers to identify which patients actually benefit from the intensified therapy. This lack of a predictive signature means applying the results in the clinic amounts to uniform escalation, likely overtreating many patients for an uncertain benefit, making it difficult to implement.

The control arm relapse rate in the SUNRISE 2 trial was only ~20%, while in the EV-303/KEYNOTE-905 trial it was ~60%. This huge discrepancy highlights that current clinical staging and selection criteria are poor at identifying patient risk, signaling an urgent need for better stratification tools like ctDNA for more effective clinical trials.